|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
14
|
|
pubmed:dateCreated |
2006-9-6
|
|
pubmed:abstractText |
The aim of this pilot study was to assess whether enfuvirtide can be discontinued in patients on long-term viral suppression. Eight patients with multidrug-resistant virus were randomly assigned to stop and 10 subjects to continue enfuvirtide. At week 48, viral rebound occurred in five (62.5%) and in no patients, respectively, (P = 0.007). The CD4 cell decrease in failure patients was 5% (P = ns). These results suggest that enfuvirtide should be maintained until new active drugs became available.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0269-9370
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
11
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1896-8
|
|
pubmed:meshHeading |
pubmed-meshheading:16954734-Antigens, CD38,
pubmed-meshheading:16954734-CD4 Lymphocyte Count,
pubmed-meshheading:16954734-CD8-Positive T-Lymphocytes,
pubmed-meshheading:16954734-Drug Resistance, Viral,
pubmed-meshheading:16954734-HIV,
pubmed-meshheading:16954734-HIV Envelope Protein gp41,
pubmed-meshheading:16954734-HIV Fusion Inhibitors,
pubmed-meshheading:16954734-HIV Infections,
pubmed-meshheading:16954734-Humans,
pubmed-meshheading:16954734-Mutation,
pubmed-meshheading:16954734-Peptide Fragments,
pubmed-meshheading:16954734-Pilot Projects,
pubmed-meshheading:16954734-Prospective Studies
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Viral failure in HIV-infected patients with long-lasting viral suppression who discontinued enfuvirtide.
|
|
pubmed:affiliation |
Lluita Contra la SIDA Foundation, AIDS Care Unit, Hospital Universitari Germans Trias i Pujol, Universitat Auntònoma de Barcelona, Badalona, Spain.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial
|
